Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?

Oncologist

Volumn 17, Issue 12, 2012, Pages 1534-1540

  Kwa, Maryann ^a   Baumgartner, Robert ^a   Shavit, Linda ^b   Barash, Irina ^a   Michael, Jeffrey ^a   Puzanov, Igor ^c   Kopolovic, Juri ^d   Rosengarten, Ora ^b   Blank, Stephanie ^a   Curtin, John P ^a   Gabizon, Alberto ^b   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Chronic kidney disease; Ovarian cancer; Pegylated liposomal doxorubicin; Renal thrombotic microangiopathy

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CREATININE; DEOXYCYTIDINE; DOXORUBICIN; FATAL OUTCOME; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RECURRENCE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TAXOIDS; THROMBOSIS; TOPOTECAN;

EID: 84871547585     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0422     Document Type: Article

References (25)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
2. Muggia F, Cannon T, Safra T et al. Delayed neoplastic and renal complications in women receiving longterm chemotherapy for recurrent ovarian cancer. J Natl Cancer Inst 2011;103:160-161.
3. Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13:1777-1785.
4. Andreopoulou E, Gaiotti D, Kim E et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007;18:716-721.
5. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003;42: 419-436.
6. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(suppl 1):S1-S266.
8. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 2892560-2572.
9. PDR. net. Doxil (doxorubicin hcl liposome). Montvale, NJ: PDR Network, LLC, 2012. Available at: http://www. pdr.net/drugpages/concisemonograph.aspx?concise_101, accessed May 15, 2012.
10. 2. Ann Oncol 2000;11:1029-1033.
11. Muggia F, Boyd L, Liebes L et al. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in secondline treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 2009;27(15 suppl):abstract 5548.
12. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer. Gynecol Oncol 2009;112:275-281.
13. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 2008; 73:994-1007.
14. Metz-Kurschel U, Kurschel E, Niederle N et al. Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin. J Cancer Res Clin Oncol 1990;116:203-206.
15. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-993.
16. Alberts DS, Muggia FM, Carmichael J et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004;31(suppl 13): 53-90.
17. Safra T, Borgato L, NicolettoMet al. Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations. J Clin Oncol 2010;28(15 suppl):abstract 5043.
18. Bertani T, Poggi A, Pozzoni R et al. Adriamycininduced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 1982;46:16-23.
19. Wang Y, Wang YP, Tay YC et al. Progressive Adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events. Kidney Int 2000;58:1797-1804.
20. Lee VW, Harris DC. Adriamycin nephropathy: A model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011;16:30-38.
21. Hirai T, Okumura K, Nishimoto Y et al. Upregulation of renal eNOS by high-sodium diet facilitates hypertension in doxorubicin-treated rats through enhanced oxidative stress. Toxicology 2006;225:81-89.
22. Gabizon A, Meshorer A, Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 1986;77:459-469.
23. Aghajanian C, Finkler NJ, Rutherford T et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2001;29:abstract LBA5007.
24. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136.
25. Fung MC, Storniolo AM, Nguyen B et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-2032.